Nintedanib

Generic Name
Nintedanib
Brand Names
Ofev, Vargatef, Nintedanib Accord
Drug Type
Small Molecule
Chemical Formula
C31H33N5O4
CAS Number
656247-17-5
Unique Ingredient Identifier
G6HRD2P839
Background

Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only tw...

Indication

Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It is also indicated for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
...

Associated Conditions
Idiopathic Pulmonary Fibrosis (IPF), Respiratory Function Impaired, Chronic Progressive Fibrosing Interstitial Lung Disease, Locally advanced Non-Small Cell Lung Carcinoma (NSCLC), Locally recurrent Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Non-Small Cell Lung Carcinoma (NSCLC)
Associated Therapies
-
Clinical Trials
Related News

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

Phase 1
Terminated
Conditions
Cancer of Pancreas
Interventions
Drug: Nintedanib
First Posted Date
2016-09-15
Last Posted Date
2024-06-03
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
14
Registration Number
NCT02902484
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

First Posted Date
2016-08-15
Last Posted Date
2016-08-15
Lead Sponsor
NHS Greater Glasgow and Clyde
Target Recruit Count
120
Registration Number
NCT02866370
Locations
🇬🇧

University College London Hospital, London, United Kingdom

🇬🇧

Great Western Hospital, Swindon, United Kingdom

🇬🇧

The Christie Hospital, Manchester, United Kingdom

and more 14 locations

Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

Phase 2
Active, not recruiting
Conditions
Malignant Pleural Mesothelioma
Interventions
Drug: Placebo
Drug: Nintedanib
First Posted Date
2016-08-11
Last Posted Date
2024-04-05
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
37
Registration Number
NCT02863055
Locations
🇧🇪

UZ Antwerpen, Antwerpen, Belgium

🇧🇪

UZ Gent, Gent, Belgium

🇮🇹

Ospedale San Paolo, Milan, Italy

and more 5 locations

Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)

First Posted Date
2016-08-05
Last Posted Date
2017-05-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT02856867

Trial Of Pembrolizumab And Nintedanib

First Posted Date
2016-08-04
Last Posted Date
2023-04-25
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
221
Registration Number
NCT02856425
Locations
🇫🇷

Hôpital Bichat, Paris, France

🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

IUCT--O, Toulouse, France

and more 2 locations

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

First Posted Date
2016-07-18
Last Posted Date
2018-07-10
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
21
Registration Number
NCT02835833
Locations
🇺🇸

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma

Phase 2
Terminated
Conditions
Sarcoma, Soft Tissue
Interventions
Drug: Nintedanib
Drug: Ifosfamide
First Posted Date
2016-06-21
Last Posted Date
2021-09-20
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
80
Registration Number
NCT02808247
Locations
🇧🇪

Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium

🇫🇷

Institut Bergonie, Bordeaux, France

🇧🇪

Cliniques Universitaires Saint-Luc (121), Brussels, Belgium

and more 10 locations

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

First Posted Date
2016-06-16
Last Posted Date
2019-01-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
274
Registration Number
NCT02802345
Locations
🇦🇺

Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia

🇫🇷

HOP Bichat, Paris, France

🇮🇳

Care Institute Of Medical Sciences, Ahmedabad, India

and more 82 locations

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Phase 4
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: placebo
Drug: nintedanib
First Posted Date
2016-06-02
Last Posted Date
2023-12-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
347
Registration Number
NCT02788474
Locations
🇨🇿

University Hospital Plzen, Plzen-Bory, Plzen, Czechia

🇧🇪

Edegem - UNIV UZ Antwerpen, Edegem, Belgium

🇯🇵

Kindai University Hospital, Osaka, Osakasayama, Japan

and more 83 locations

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Phase 2
Terminated
Conditions
Colorectal Neoplasms
Interventions
Drug: Nintedanib
Drug: Capecitabine
First Posted Date
2016-05-23
Last Posted Date
2018-10-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1
Registration Number
NCT02780700
Locations
🇺🇸

Fort Wayne Medical Oncology Hematology, Fort Wayne, Indiana, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy